ArticleWorld journal of stem cells2026
Co-expression of cancer stem cell markers CD24 and CD133 in gastric cancer tissues: Clinicopathological and prognostic significance.
Article in World journal of stem cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is one of the most common malignant tumors of the digestive system worldwide, the prognosis of patients with advanced GC remains poor.
aimTo evaluate the combined expression characteristics of cancer stem cell markers CD24 and CD133 in GC pathological tissues, and to explore their association with patients' clinicopathological parameters and postoperative survival outcomes.
methodsA total of 304 GC patients who underwent surgical treatment in our hospital from January 2018 to January 2020 were retrospectively included. Immunohistochemistry was used to detect the protein expression of CD24 and CD133 in tumor tissues, adjacent tissues, and normal gastric mucosa tissues. Based on staining intensity and the proportion of positive cells, expression levels were classified into low and high expression, while clinicopathological parameters were recorded.
resultsAmong the 304 patients, 155 cases (50.99%) were CD24 positive, including 91 low-expression and 64 high-expression; 133 cases (43.75%) were CD133 positive, including 81 low-expression and 52 high-expression. There were 74 cases (24.34%) with double positivity and 81 cases (26.64%) with double negativity. Compared with tumor tissues, the positive rates of CD24 and CD133 in normal gastric tissues and adjacent tissues were significantly lower (
conclusionCD24 and CD133 exhibit high positive detection rates in GC tissues, and their co-positivity is closely associated with tumor stage progression and significantly indicates unfavorable survival outcomes. The co-expression of CD24/CD133 may reflect higher aggressiveness and metastatic potential of GC, serving as a potential prognostic marker and a direction for targeted therapeutic strategies. However, as this is a single-center retrospective study with limitations such as patient loss to follow-up and sample size, further prospective, multicenter, and mechanistic studies are required to validate its clinical applicability and biological role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.